Expression And Clinical Significance Of Peroxiredoxin Ⅲ Protein In Ovarian Epithelial Serous Cystadenocarcenoma

ObjectiveThe recuremce rate and mortality rate in ovarian cancer is the highest in female generative organ tumor,Its disease rate is the second in female generative organ tumor, second only to cervical carcinoma,Most ovarian cancers are epithelial serous cystadenocarcenomas,to this there are little ideal early diagnostic method.Once discovered,it belongs to advanced stage.So far,the pathogenesis of ovarian cancer has not distincted.Therefore,the research most scholars investigated focus on the early diagnosis,etiopathogenisis and nosogenesis of ovarian cancer.PRDXⅢis a member of Peroxiredoxins(PRDXs) family discovered recently.It is an antioxidative related protein in cells,there are some researches show that the expression of PRDXⅢincreases in liver cancer,mesothelioma,breast cancer and so on.But there is no report about it in ovarian cancer at home and abroad.The previous work of our research is to compare and analyze the ovarian epithelial serous cystadenocarcenoma and nomal ovarian epithelium,screen the distinct expressed protein,PRDXⅢ,and then to detect the expression of PRDXⅢin ovarian epithelial serous cystadenocarcenoma,thereby inspect and verify its veracity.Our research is to investigate the expression of PRDXⅢin ovarian epithelial serous cystadenocarcenoma,ovarian epithelial serous carcinoid and nomal ovarian epithelium,and find out the relation in its expression and menostasia,as well as cell differentiation,hope to investigate whether PRDXⅢis interrelated with the cause and development of ovarian epithelial serous cystadenocarcenoma or not.Materials and Methods65 cases of ovarian epithelial serous cystadenocarcenoma were obtained from patients who undergone operation for ovarian epithelial serous cystadenocarcenoma from 2003,9 to 2007,7 in Shengjing hospital.Among this there are 24 cases belonging to premenopause and 41 cases belonging to postmenopausal.65 cases of cases of ovarian epithelial(overian cancer group) serous cystadenocarcenoma included 18 cases ofⅠstage,18 cases ofⅡstage,29 cases ofⅢ-Ⅳstage(FIGO,2000 years).In 65 cases of ovarian epithelial serous cystadenocarcenoma,There were 33 cases of low differentiation,22 cases of moderate differentiation and 10 cases of well differentiation, besides,there are 24 case of ovarian epithelial serous carcinoid(benign group);more over,we choose 19 cases of nomal ovarian tissue who undergone operation for cervical carcinoma to contrast(nomal group).The age of the patients ranged from 28 and 78 years and the mean age was 55.2±11.1 years.All patients accepted neither adjuvant radiotherapy,chemotherapy nor hormone therapy before operation.All samples had a definitive pathological diagnosis.Immunohistochemistry were used to investigate the expression of PeroxiredoxinⅢin 19 cases of nomal ovarian tissue,24 cases of ovarian epithelial serous carcinoid,65 cases of ovarian epithelial serous cystadenocarcenoma. All data was expressed as X~2 Test and Fisher precice propability Test.SPSS version 13.0 was used to performed statistical analysis,P＜0.05 was considered statistically significant.Results1,The expression of PeroxiredoxinⅢin all groupsWhen we performed immunohistochemistry to detect all the samples,we observed the colouration of PeroxiredoxinⅢis in cytoplasm,pale yellow to dark brown.The expression of PRDXⅢin ovarain cancer group is more than benign group and nomal group obviously(X~2=15.20,38.11,P＜0.01).There is no significant differences between the expression of PRDXⅢin benign group and nomal group(X~2=3.58,P＞0.05).2,The relationship between PeroxiredoxinⅢand clinicopathological parametersThe expression of PRDXⅢin ovarian epithelial(overian cancer group) serous cystadenocarcenoma of every stage are following:Ⅰstage 88.9%,Ⅱstage 88.9%,Ⅲ-Ⅳstage 93.1%,there is no significant differences between all stages;The lower the cell differentiation degree is,the expression of PRDXⅢis higher,and there are significant differences between low differentiated ovarian cancer and well-differentiated,moderate-differentiated carcinoma(X~2=4.76,P＜0.05).3,There is no significant differences between premenopause cases and postmenopause casesThere is no significant differences between the expression of PRDXⅢin premenopause and postmenopausal group(X~2=0.064,P＞0.05).Conclusion1,The colouration of PeroxiredoxinⅢis in cytoplasm.and the expression of PRDXⅢin ovarian epithelial serous cystadenocarcenoma was more than in ovarian epithelial serous carcinoid and in nomal ovarian tissue.2,The lower the cell differentiation degree is,the expression of PRDXⅢis higher,But there is no relations between all clinical stages.3,The expression of PRDXⅢwasn't correlated with menopause or not in cancer group.